Southwest Medical University Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2019
NCT03941431
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Affiliated Hospital of Southwest Medical University | Chinese Medicine Hospital Affiliated to Southwest Medical University | Southwest Medical University, Hospital of Traditional Chinese Medicine | The Affiliated Hospital Of Southwest Medical University

Active Ingredients

Drugs in Phase 4 Trials (3)

Azvudine (1 trial)

nirmatrelvir (Paxlovid) (1 trial)

ritonavir (Norvir) (1 trial)

Drugs in Phase 3 Trials (3)

escitalopram (lexapro) (1 trial)

lactulose (cephulac) (1 trial)

polyethylene glycol (2 trials)

Drugs in Phase 2 Trials (4)

chlorotrianisene (tace) (1 trial)

jueyin (1 trial)

sintilimab (2 trials)

tislelizumab (1 trial)

Drugs in Phase 1 Trials (1)

89zr-cd147 (1 trial)

Drugs in Other Trials (2)

dextrose (1 trial)

linaclotide (linzess) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Colorectal Neoplasms (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 2)

Peritoneal Neoplasms (Phase 3)

Psoriasis (Phase 2)

Rectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 13